Overall verdict
Buy
6.5/10
1-year performance
+46.27%
Score breakdown
Up 46.3% over 1 year, 51% of the 52-week range.
9 analysts, target +3.1% vs the price.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity ;
Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials ; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
Germany
CEO
Niels Riedemann
Founded
2007
Employees
65
Revenue / employee
453 EUR
Next earnings
November 6, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
2.95 USD
52-week low
0.80 USD
1-year performance
46.27%
Rising
Year-to-date performance
90.29%
Rising
Drawdown
-35.90%
Major drawdown
Position in the 52-week range
51% of range
ROE -494.7%.
Net margin
—
Sector -229.23%|S&P 12.97%
Gross margin
—
Return on equity (ROE)
-494.71%
Negative
Sector -58.12%|S&P 16.52%
Return on invested capital (ROIC)
—
Free cash flow margin (FCF)
—
Revenue to net income
Growth
10.0/10Revenue up 520.3% over 1 year.
Revenue (trailing 12 months)
—
Revenue growth (1y)
520.29%
Hyper-growth
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.3x|S&P 23.0x
Forward P/E (adjusted)
—
EV / EBITDA
—
Sector 13.4x|S&P 14.5x
PEG
—
Sector 0.12|S&P 0.86
Market cap
254M EUR
Financial strength
10.0/10Cash covers 19025.3% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-107.87%
Net cash
Cash
161M EUR
Cash / market cap
63.51%
Very solid
Cash / total debt
19025.26%
Net cash
Net debt
-160M EUR
Equity
149M EUR
Closed daily candles, 2 years
Last close on September 24, 2026: 1.93 USD
- MM202.12
- MM502.00
- MM2001.57
- RSI 1440.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+6.38%
200-day average slope, 3 months
+16.54%
50-day average slope, 1 month
+2.79%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.97 % per day
Volatility change
-46.88%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.28 (8) | -0.27 (5) | 0 (7) | — | -32 (7) |
| 2027 | -0.35 (8) | -0.35 (5) | 0 (7) | — | -44 (7) |
Amounts in millions of EUR, EPS in EUR per share. In brackets, the number of analysts. Consensus as of September 16, 2026.
Same sub-industry: 734 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RCKT | 6.8 | N/A | 332M USD | Not meaningful (loss) | — | — | -4.5 % | 1.4x | -51.4 % | -14.6 % | ||
| 2 | CUV | 6.5 | 6.3 | 294M USD | 12.4x | 36.1 % | -1.0 % | 13.2 % | -6.0x | 8.3 % | -29.0 % | ||
| 3 | IFRX | 6.5 | N/A | 289M USD | Not meaningful (loss) | — | 520.3 % | — | — | — | 46.3 % | ||
| 4 | XFOR | 4.9 | 2.5 | 308M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -13.3 % | ||
| 5 | IKT | 4.4 | 0.9 | 300M USD | Not meaningful (loss) | — | — | -52.0 % | 2.4x | -14.2 % | 29.6 % | ||
| 6 | CATX | 4.4 | 1.6 | 299M USD | Not meaningful (loss) | -28516.1 % | -72.1 % | -39.2 % | 2.1x | -40.6 % | -21.4 % | ||
| 7 | SANN | 4.0 | 3.5 | 286M USD | Not meaningful (loss) | -63.8 % | 97.3 % | -62.8 % | -2.3x | -15.4 % | 25.2 % | ||
| 8 | ALERS | 3.6 | 4.1 | 287M USD | 51.9x | 2.9 % | 9.1 % | 2.6 % | -0.1x | 1.9 % | -1.4 % | ||
| 9 | AMRN | 3.3 | 3.7 | 290M USD | Not meaningful (loss) | -14.6 % | -42.6 % | -5.9 % | 14.7x | 5.4 % | -12.0 % |
